Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Oncology

Intestinal vs. Pancreatobiliary: The Two 'Flavors' of Ampullary Cancer

At a Glance

Ampullary cancer has two main subtypes: intestinal and pancreatobiliary. The intestinal type behaves more like colon cancer, while the pancreatobiliary type acts like pancreatic cancer. Knowing your subtype is crucial because it dictates which chemotherapy and targeted treatments will work best.

While your diagnosis is “ampullary cancer,” this term actually covers two very different diseases that just happen to start in the same small location. Pathologists look at the tumor cells under a microscope to determine their “flavor” or histological subtype. Knowing your subtype is perhaps the single most important piece of information you can have, as it tells your doctors how the cancer is likely to behave and which treatments might work best [1][2].

The Two Main Subtypes

The ampulla of Vater is a meeting point for two different types of lining: the intestinal lining of the duodenum and the ductal lining of the pancreas. Depending on which cells the cancer originates from, it will fall into one of two categories:

1. Intestinal Subtype

This subtype arises from the cells that line the small intestine.

  • Behavior: It tends to behave more like colorectal cancer [3].
  • Prognosis: Historically, this type is associated with a more favorable outlook and higher 5-year survival rates [1][4].
  • Treatment Path: Doctors may lean toward chemotherapy drugs commonly used for colon cancer, such as 5-fluorouracil (5-FU) or oxaliplatin [5].

2. Pancreatobiliary Subtype

This subtype arises from the cells lining the bile or pancreatic ducts.

  • Behavior: It behaves more like pancreatic cancer, which is typically more aggressive [3].
  • Prognosis: This type generally has a more challenging prognosis and lower survival rates compared to the intestinal type [1][6].
  • Treatment Path: Doctors often treat this with drugs used for pancreatic or bile duct cancers, such as gemcitabine or nab-paclitaxel [7].

Rare and Unusual Variants

In a small number of cases (roughly 2-3%), the tumor may show rare patterns:

  • Signet Ring Cell Carcinoma: This is a rare variant where the cells look like rings under a microscope [8]. While once thought to be universally more aggressive, recent research suggests that if caught early and removed surgically, the outcomes may be similar to other types [9][10].
  • Mixed Type: Sometimes a tumor contains a mix of both intestinal and pancreatobiliary cells, making the treatment choice more complex [3].

Why the Distinction Matters

The “label” of your subtype drives the precision medicine approach your team will take. Because the two subtypes respond differently to different drugs, using a “pancreatic-style” treatment on an “intestinal-style” tumor might not be as effective as a targeted colon-cancer regimen [5][3].

Increasingly, doctors are moving beyond just looking at the cells under a microscope. They are using genomic profiling to look at the tumor’s DNA. This can reveal whether a tumor has “colorectal-like” or “pancreatic-like” mutations, providing an even more accurate map for your treatment than the subtype alone [3][11]. Identifying markers like MSI-H (microsatellite instability) or HER2 expression can also open doors to specialized therapies like immunotherapy [12][13].

Common questions in this guide

What is the intestinal subtype of ampullary cancer?
The intestinal subtype arises from the cells lining the small intestine. It tends to behave similarly to colorectal cancer and historically has a more favorable long-term prognosis compared to the pancreatobiliary type.
What is the pancreatobiliary subtype of ampullary cancer?
The pancreatobiliary subtype develops from the cells lining the bile or pancreatic ducts. It typically behaves more like pancreatic cancer, meaning it is often more aggressive and requires a different treatment approach.
How does my ampullary cancer subtype affect my treatment options?
Your specific subtype tells your oncology team which chemotherapy drugs are most likely to be effective. Intestinal tumors are often treated with colon cancer medications like 5-FU, while pancreatobiliary tumors usually respond better to pancreatic cancer drugs like gemcitabine.
Why is genomic testing important for ampullary cancer?
Genomic profiling looks directly at the DNA mutations inside your tumor rather than just its shape under a microscope. This testing can reveal specific markers, like MSI-H or HER2, which may make you a candidate for targeted therapies or immunotherapy.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which histological subtype—intestinal or pancreatobiliary—did the pathologist identify in my biopsy or surgical specimen?
  2. 2.Were specific markers (like MUC1, MUC2, or CDX2) used to confirm my tumor's subtype?
  3. 3.Based on my subtype, are you recommending a chemotherapy regimen more common for colon cancer (like 5-FU/oxaliplatin) or pancreatic cancer (like gemcitabine)?
  4. 4.Does my pathology report mention any rare features, such as signet ring cells or high-grade differentiation?
  5. 5.Have you considered genomic testing (molecular profiling) to see if my tumor has 'colorectal-like' or 'pancreatic-like' genetic markers?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma.

    Zimmermann C, Wolk S, Aust DE, et al.

    Scientific reports 2019; (9(1)):12676 doi:10.1038/s41598-019-49179-w.

    PMID: 31481741
  2. 2

    Ampulla of Vater carcinoma: advancement in the relationships between histological subtypes, molecular features, and clinical outcomes.

    Liang H, Zhu Y, Wu YK

    Frontiers in oncology 2023; (13()):1135324 doi:10.3389/fonc.2023.1135324.

    PMID: 37274233
  3. 3

    Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care.

    Chakraborty S, Ecker BL, Seier K, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2021; (27(21)):5891-5899 doi:10.1158/1078-0432.CCR-21-1906.

    PMID: 34433650
  4. 4

    Prognostic impact of immunohistochemical expression of CK7 and CK20 in curatively resected ampulla of Vater cancer.

    Yun SP, Seo HI

    BMC gastroenterology 2015; (15()):165 doi:10.1186/s12876-015-0396-x.

    PMID: 26603157
  5. 5

    Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG).

    Kalem A, Kus T, Gokcek S, et al.

    Journal of clinical medicine 2025; (14(16)) doi:10.3390/jcm14165868.

    PMID: 40869694
  6. 6

    Very early recurrence following pancreaticoduodenectomy in patients with ampullary cancer.

    Park HM, Park SJ, Han SS, et al.

    Medicine 2019; (98(44)):e17711 doi:10.1097/MD.0000000000017711.

    PMID: 31689805
  7. 7

    Nab-Paclitaxel and Gemcitabine as First-Line Treatment of Metastatic Ampullary Adenocarcinoma with a Novel R-Spondin2 RNA Fusion and NTRK3 Mutation.

    Linscott MP, Markus H, Sennett M, et al.

    Biomedicines 2023; (11(8)) doi:10.3390/biomedicines11082326.

    PMID: 37626821
  8. 8

    Poorly Cohesive (Signet Ring Cell) Carcinoma of the Ampulla of Vater.

    Tuncel D, Basturk O, Bradley KT, et al.

    International journal of surgical pathology 2020; (28(3)):236-244 doi:10.1177/1066896919880968.

    PMID: 31612756
  9. 9

    Signet ring cell adenocarcinoma of the ampulla of Vater: does the presence of signet ring cells always suggest a poorer outcome?

    Nandy K, Dhaiya A, Vipin T, et al.

    Langenbeck's archives of surgery 2025; (410(1)):195 doi:10.1007/s00423-025-03708-6.

    PMID: 40522349
  10. 10

    Signet ring cell carcinoma of the Ampulla of Vater: outcomes of patients in the United States.

    Kinslow CJ, May MS, Kozak M, et al.

    HPB : the official journal of the International Hepato Pancreato Biliary Association 2020; (22(12)):1759-1765 doi:10.1016/j.hpb.2020.03.024.

    PMID: 32317226
  11. 11

    Ampullary Adenocarcinoma: A Review of the Mutational Landscape and Implications for Treatment.

    Tsagkalidis V, Langan RC, Ecker BL

    Cancers 2023; (15(24)) doi:10.3390/cancers15245772.

    PMID: 38136318
  12. 12

    Molecular Targets and Therapies for Ampullary Cancer.

    Patel MA, Kratz JD, Carlson AS, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2024; (22(2 D)).

    PMID: 38181507
  13. 13

    Association of PD-L1 Expression with Lymph Node Metastasis and Clinical Stage in Ampulla of Vater Cancer: An Observational Study.

    Andrianto A, Rudiman R, Ruchimat T, et al.

    Cancer management and research 2025; (17()):965-974 doi:10.2147/CMAR.S513961.

    PMID: 40391126

This page explains ampullary cancer subtypes and pathology for educational purposes only. Your pathologist and oncologist are the best sources for interpreting your specific biopsy results and recommending a treatment plan.

Get notified when new evidence is published on Carcinoma of the ampulla of Vater.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.